By PPN News Staff
The FDA expanded the indication for pneumococcal 15-valent conjugate vaccine (PCV15; Vaxneuvance, Merck) to include children 6 weeks through 17 years of age.
PCV15 is now indicated for active immunization in people 6 weeks and older to prevent invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F.
The FDA’s approval was based on data from seven randomized, double-blind clinical studies